RPAM
Rhenman & Partners Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.39M | Buy |
93,100
+11,100
| +14% | +$404K | 0.43% | 61 |
|
|
2025
Q1 | $2.97M | Buy |
+82,000
| New | +$2.97M | 0.34% | 60 |
|
|
2020
Q4 | – | Sell |
-61,500
| Closed | -$5.06M | – | 93 |
|
|
2020
Q3 | $5.06M | Hold |
61,500
| – | – | 0.45% | 64 |
|
|
2020
Q2 | $4.81M | Sell |
61,500
-7,024
| -10% | -$549K | 0.52% | 63 |
|
|
2020
Q1 | $3.05M | Buy |
+68,524
| New | +$3.05M | 0.43% | 67 |
|
|
2018
Q1 | – | Sell |
-95,000
| Closed | -$4.41M | – | 97 |
|
|
2017
Q4 | $4.41M | Sell |
95,000
-5,000
| -5% | -$232K | 0.6% | 60 |
|
|
2017
Q3 | $5.33M | Buy |
100,000
+64,427
| +181% | +$3.43M | 0.68% | 59 |
|
|
2017
Q2 | $2.21M | Buy |
+35,573
| New | +$2.21M | 0.32% | 76 |
|
|
2016
Q3 | – | Sell |
-10,000
| Closed | -$489K | – | 116 |
|
|
2016
Q2 | $489K | Sell |
10,000
-30,000
| -75% | -$1.47M | 0.09% | 91 |
|
|
2016
Q1 | $2.53M | Buy |
+40,000
| New | +$2.53M | 0.5% | 69 |
|